The EGFR signalingpathway is frequently dysregulated in early stage breast cancer andis associated with altered circulating EGFR levels, supporting itsutility as both a circulating biomarker and therapeutic target. Similarly, the AMPK signaling pathway actsas a central regulator of cellular metabolism and immune modulationwithin the tumor microenvironment, positioning it as a promising targetfor cancer therapy. Together, EGFR andAMPK pathways represent biological meaningful targets in breast cancerpathophysiology and are actively pursued in precision oncology. This evidence concerns the gene EGFR and cancer.